Shuttle Pharmaceuticals delays quarterly report over change-in-control accounting
SHPH•Shuttle Pharmaceuticals delayed its Form 10-Q for the quarter ended September 30, 2026, citing a change-in-control analysis. The report is expected within five calendar days of the filing deadline.
1. Accounting change delays filing
Shuttle Pharmaceuticals delayed its Form 10-Q for the quarter ended September 30, 2026, primarily because of a change-in-control analysis. The September 9 conversion of Series B-1 Preferred Stock into common stock triggered the change in control. The conversion will be accounted for as a reverse asset acquisition, with United Dogecoin as the accounting acquirer. Historical financial statements will reflect United Dogecoin, resulting in significantly different operating results from those previously reported for the corresponding prior-year period.




